Conferences
ESMO 2018: Pembrolizumab for High-Risk Non–Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to BCG: Phase 2 Keynote-057 Trial
October 20, 2018
ESMO 2018: When is a Cancer Patient Cured?
October 20, 2018
ESMO 2018: The Right to be Forgotten - Access to Loan-Related Insurance for French Cancer Survivors
October 20, 2018
ESMO 2018: Immunotherapy in Renal and Bladder Cancers
October 20, 2018
ESMO 2018: Immune Therapies Going Adjuvant: Benefits Versus Risks: How Long Should We Treat Patients?
October 20, 2018
ESMO 2018: 12-Year Follow-Up of GETUG-12, A Phase 3 Trial of Docetaxel-Based Chemotherapy in High-Risk Localized Prostate Cancer
October 20, 2018
ESMO 2018: Cabazitaxel vs Abiraterone or Enzalutamide in Poor Prognosis Metastatic Castration-Resistant Prostate Cancer Patients
October 19, 2018
ESMO 2018: A Randomized Phase 2 Study of Cabazitaxel vs Abiraterone or Enzalutamide in Poor Prognosis Metastatic Castration-Resistant Prostate Cancer
October 19, 2018
Huge Variations Between Countries in Time for Reimbursement Decisions on New Cancer Drugs
October 19, 2018
Financial Impacts of Cancer Found to Intensify Disease Burden Among German Patients
October 16, 2018
NSAUA 2018: Non-Metastatic Castration Resistant Prostate Cancer
October 14, 2018
NSAUA 2018: The Curability of Invasive Bladder Cancer
October 13, 2018